Navigation Links
Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
Date:5/30/2008

PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that it is implementing the next step in its ongoing effort to focus its resources on the company's clinical and later-stage discovery programs. This effort includes an immediate workforce reduction of approximately 15 percent through attrition and termination of positions as well as a decrease in other expenses through improved operational efficiencies and increased financial discipline. The company's annual operating expenditures are expected to decrease by at least $10 million in 2009.

"We believe that, with the recent announcement of our positive Phase 2a results for PS433540 (DARA), it is the appropriate time to continue executing our plan to allocate a greater share of our resources towards our later-stage programs," said Joseph A. Mollica, Ph.D., Chairman of the Board of Directors and Interim President and Chief Executive Officer of Pharmacopeia. "We are grateful for the contributions of the highly talented individuals whose positions are impacted by these decisions and wish them success in their future endeavors."

"In order to maximize shareholder value it is essential that we focus our efforts on the programs that can provide the greatest return. In addition to PS433540, these programs include: PS178990, our Selective Androgen Receptor Modulator (SARM) which we believe will progress into Phase 2 testing in the first half of 2009; PS031291, our oral CCR1 development candidate for which we intend to initiate clinical development for the treatment of rheumatoid arthritis in early 2009; and our JAK3 program for the topical treatment of psoriasis which we expect to enter preclinical development in 2009. Discovery research remains a core strength of Pharmacopeia and will be increasingly focused on the discovery and advancement of clinical candidates that we can indep
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
3. Pharmacopeia Announces Management Team Changes
4. Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
7. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
8. Pharmacopeia to Host First Quarter 2008 Financial Results Webcast and Conference Call
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
11. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s Flametec ... competitive in the semiconductor, clean room and medical ... product quality and productivity, according to Dwight Leatherwood, ... 1980 in Lewisville, TX, Leatherwood Plastics ... the business. Much of Leatherwood’s equipment building relies ...
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:9/18/2014)... 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... concurrent but separate underwritten offerings of 10,000,000 shares of ... of $2.00 per share, for expected gross proceeds of ... Convertible Preferred Stock at a price to the public ... $20 million. Each share of Series A Convertible Preferred ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... Reportlinker.com announces that a new market ... Neurology Devices Market Outlook ... Interventional Neurology and Other ... Market Outlook in China to 2017 – ...
... A team of scientists at Penn State University, the ... developed a method for recreating a schizophrenic patient,s own ... effectively in a Petri dish. The method brings researchers ... schizophrenia. The method also is expected to be used ...
... Researchers here have created the first electronic circuit ... devices that utilize the spin of electrons ... Johnston-Halperin, assistant professor of physics, and his team ... material that is under development in colleague Arthur ...
Cached Biology Technology:Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 2Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 4Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 5Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 6Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 7Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 8Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 9Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 10Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 11Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 12Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 13Scientists recreate brain cells from skin cells to study schizophrenia safely 2Scientists recreate brain cells from skin cells to study schizophrenia safely 3Researchers advance toward hybrid spintronic computer chips 2Researchers advance toward hybrid spintronic computer chips 3
(Date:9/18/2014)... devastated algal forests in the eastern Mediterranean Sea pose ... their distribution continues to expand as the climate warms, ... team of researchers led by Dr Adriana Vergs of ... Institute for Advanced Studies in Spain, is published in ... team surveyed more than 1000 kilometres of coastline in ...
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... research has found clownfish larvae can swim up to 400 ... able to cope with environmental change. , Clownfish spend their ... but as babies they must wander the open ocean, says ... Excellence for Coral Reef Studies (Coral CoE) at James Cook ... go, but now we,ve been given a rare glimpse into ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2How stress tears us apart 2Nemo's epic journey to find a new home 2
... Singapore and Germany have identified that the proteins lamin ... for holding silent genes in their correct position at ... heterochromatin . A deviation from their normal position will ... vascular disease and muscle wasting. 2. For hundreds ...
... Vienna it was impossible not to notice that the blackbirds ... the courtyards of the inner city nor woke tired partygoers ... longer there. Thankfully, they gradually reappeared and a few ... But the sudden crash in numbers was alarming and ...
... by the National Science Foundation with a $400,000 Early ... devices, which promise to improve 3D tissue and cell ... Texas College of Engineering in 2007, has developed a ... cells on microchips. , Her devices produce more accurate ...
Cached Biology News:A*STAR scientists' groundbreaking discovery of nucleus structure crucial to understanding diseases 2Forensic pathology: tracing the origin of the Usutu Virus 2
... 1 Block MBS Start up kit. ... software and choice of 1 MultiBlock ... to 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding ...
... is Thermo Electron's most advanced personal gradient ... to use sophisticated onboard software and a ... to offer performance, accuracy and simplicity in ... of customer driven features built up on ...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
... a derivative of Taq DNA polymerase. It ... DNA polymerase. Expressed from a gene construct ... bypassing the 5'-3' exonuclease domain of the ... highly active and even more heat-stable DNA ...
Biology Products: